Core Insights - AstraZeneca reported earnings of $2.38 per share and $15.19 billion in third-quarter sales, exceeding analyst expectations of $2.29 per share and $14.78 billion in sales [1][2] - Revenue from cancer drugs increased by 19% to $6.64 billion, making up 44% of total sales for the quarter [1] - The company reiterated its guidance, expecting core earnings to rise by a low double-digit percentage and sales to increase by a high single-digit percentage [2] Financial Performance - In the same period last year, AstraZeneca earned $2.08 per share with $13.57 billion in sales [2] - The stock rose by 3.1% to $83.63 in premarket trading following the earnings report [2] Market Position - Analysts project AstraZeneca's earnings for the year to be $9.14 per share with total sales of $58.17 billion [2]

Core Insights - Amgen reported third-quarter 2025 adjusted earnings of $5.64 per share, exceeding the Zacks Consensus Estimate of $5.00 per share, with a year-over-year earnings increase of 1% driven by higher revenues despite increased operating costs and taxes [1] - Total revenues reached $9.6 billion, surpassing the Zacks Consensus Estimate of $8.9 billion, marking a 12% year-over-year increase [1] Revenue Breakdown - Total product revenues increased by 12% year-over-year to $9.17 billion, with volume growth of 14% offset by a 4% negative impact from pricing [2] - Other revenues amounted to $420 million, reflecting a 19.3% year-over-year increase [2] Key Drug Performance - Evenity sales reached $541 million, up 36% year-over-year, exceeding both the Zacks Consensus Estimate of $519 million and the model estimate of $463.9 million [3] - Repatha generated revenues of $794 million, a 40% year-over-year increase, beating the Zacks Consensus Estimate of $720 million and the model estimate of $672.2 million [3] - Prolia revenues were $1.14 billion, up 9% year-over-year, significantly surpassing the Zacks Consensus Estimate of $911 million and the model estimate of $812.8 million [4] - Xgeva delivered revenues of $539 million, flat year-over-year, but exceeded the Zacks Consensus Estimate of $428 million and the model estimate of $408.6 million [5] - Blincyto sales were $392 million, a 20% increase year-over-year, but missed the Zacks Consensus Estimate of $413 million [7] - Otezla sales were $585 million, up 4% year-over-year, beating the Zacks Consensus Estimate of $582 million but missing the model estimate of $648.2 million [8] - Enbrel revenues declined by 30% year-over-year to $580 million, missing the Zacks Consensus Estimate of $645 million but beating the model estimate of $530.4 million [9] - Tezspire recorded sales of $377 million, a 40% year-over-year increase, exceeding both the Zacks Consensus Estimate of $364 million and the model estimate of $270.6 million [10] Cost and Margin Analysis - Adjusted operating margin decreased by 2.5 percentage points to 47.1%, with adjusted operating expenses rising by 18% to $5.25 billion [14] - R&D expenses increased by 31% year-over-year to $1.89 billion, reflecting ongoing investment in the late-stage pipeline [14] Future Outlook - Amgen raised its 2025 revenue and earnings guidance, expecting total revenues between $35.8 billion and $36.6 billion, and adjusted earnings per share in the range of $20.60 to $21.40 [15] - The company anticipates continued growth from key drugs like Repatha, Evenity, Tezspire, and its biosimilar portfolio, although erosion from biosimilars of Prolia and Xgeva may offset some growth [21] Pipeline Developments - Amgen is advancing its obesity drug MariTide, which has shown strong efficacy in clinical studies, with six global phase III studies currently underway [16][17] - Enrollment has been completed in two phase III studies for MariTide, with ongoing studies for cardiovascular disease and heart failure [18]

Core Viewpoint - The healthcare sector has underperformed compared to the broader market in recent years, yet Amgen Inc. (AMGN) presents attractive growth opportunities for long-term investors [1] Group 1: Company Analysis - Amgen Inc. is highlighted as a company with strong growth prospects despite the overall sector's lagging performance [1] - The investment strategy includes a mix of classic dividend growth stocks, Business Development Companies, REITs, and Closed End Funds to enhance investment income while achieving total returns comparable to traditional index funds [1] Group 2: Investment Strategy - A hybrid investment approach combining growth and income is suggested as an effective method to achieve returns on par with the S&P [1]

Although the healthcare sector has lagged behind the rest of the market over the last few years, I believe that Amgen Inc. ( AMGN ) still offers attractive growth prospects to long-term investors. TheFinancial analyst by day and a seasoned investor by passion, I've been involved in the world of investing for over 15 years and honed my skills in analyzing lucrative opportunities within the market.I specialize in uncovering high quality dividend stocks and other assets that offer potential for long term-growt ...

Core Insights - Pfizer and Novo Nordisk are engaged in a competitive bidding war for the obesity biotech Metsera, with both companies increasing their offers as of Monday [3][4] - Metsera has indicated that Novo Nordisk's latest bid of up to $10 billion is superior to Pfizer's revised offer of approximately $8.1 billion [9][10] Group 1: Bidding War Timeline - Pfizer initially proposed to acquire Metsera for $4.9 billion, potentially rising to $7.3 billion with future payments, aiming to enter the obesity market after previous setbacks [5] - Novo Nordisk launched a competing bid valuing Metsera at around $6 billion, or up to $9 billion, prompting Pfizer to renegotiate its offer within a four-business-day deadline [6] - Following Novo Nordisk's bid, Pfizer filed lawsuits against both Novo Nordisk and Metsera, seeking to block the termination of its merger agreement [7][16] Group 2: Market Context and Implications - Metsera, founded in 2022, has a pipeline of oral and injectable treatments, including a GLP-1 drug and a monthly amylin treatment, which could be less frequent than existing weekly injections [11] - The acquisition of Metsera is crucial for Pfizer to penetrate the lucrative obesity market, especially after facing challenges with its own weight loss candidates [12] - Novo Nordisk, a pioneer in the weight loss drug market, is under pressure to regain market share lost to competitors like Eli Lilly and is facing new entrants such as Amgen and Roche [13][14] Group 3: Legal and Regulatory Aspects - Pfizer's lawsuits argue that Novo Nordisk's acquisition of Metsera would reinforce its dominant position in the obesity market by eliminating a potential competitor [16] - Pfizer's first lawsuit seeks to prevent Metsera from terminating its existing merger deal, claiming that Novo Nordisk's offer is not likely to be completed due to regulatory risks [17] - A Delaware judge has scheduled a hearing to review the bidding process, indicating ongoing legal complexities in the acquisition battle [18]

Corporate Earnings Drive Pre-Market Activity - Amgen Inc. reported a 12% increase in total revenues to $9.6 billion and non-GAAP EPS of $5.64, exceeding forecasts and leading to a 3% rise in stock [3] - Lumentum Holdings Inc. saw a 17% stock increase after reporting Q3 2025 EPS of $0.57 on revenues of $425.2 million, driven by growth in its Cloud and Networking segment [4] - Rivian Automotive, Inc. reported Q3 2025 revenues of $1.56 billion, surpassing estimates, with a narrower loss per share of -$0.65 and a 47% year-over-year increase in automotive sales [5] - Johnson Controls International plc reported an adjusted EPS of $1.05 and sales of $6.1 billion, representing a 6% organic increase year-over-year, with an 11% growth in backlog [6] - The New York Times Company added 460,000 digital-only subscribers, boosting total revenue by 9.5% year-over-year to $700.8 million [7] Media and Global Trade Developments - China's Foreign Minister announced willingness to negotiate a free trade agreement with the European Union, emphasizing cooperation over rivalry [9] - The New York Times Company demonstrated strength in digital transformation, contributing to its revenue growth [7] Crude Oil Markets Face Headwinds - WTI crude oil prices are trading near $60.59, facing downward pressure from a stronger U.S. dollar and increased U.S. crude inventories [10] - OPEC+ has paused output hikes for Q1 2026, agreeing to a modest increase in December, but market sentiment remains cautiously bearish [10]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Amgen reported revenue of $9.56 billion for the quarter ended September 2025, reflecting a 12.4% increase year-over-year and a 6.87% surprise over the Zacks Consensus Estimate of $8.94 billion [1] - The earnings per share (EPS) for the quarter was $5.64, which is an increase from $5.58 in the same quarter last year, resulting in a 12.8% surprise over the consensus EPS estimate of $5.00 [1] Financial Performance Metrics - Product sales for Neulasta in the ROW were $20 million, slightly above the estimated $19.55 million, but down 23.1% year-over-year [4] - Neulasta sales in the U.S. reached $72 million, exceeding the estimate of $60.9 million, but down 14.3% from the previous year [4] - XGEVA sales in the ROW were $182 million, surpassing the average estimate of $144.77 million, marking an 8.3% year-over-year increase [4] - Enbrel sales in the ROW were $6 million, below the estimated $7.36 million, reflecting a 25% decline year-over-year [4] - Other revenues amounted to $420 million, exceeding the average estimate of $373.34 million, with a year-over-year increase of 19.3% [4] - Total product sales were $9.14 billion, surpassing the estimated $8.55 billion, representing a 12.1% increase year-over-year [4] - BLINCYTO total sales were $392 million, slightly below the estimate of $412.7 million, but showing a 19.9% increase year-over-year [4] - Otezla total sales reached $585 million, slightly above the estimate of $582.08 million, with a year-over-year increase of 3.7% [4] - Total sales for Neulasta were $92 million, exceeding the estimate of $79.77 million, but down 16.4% year-over-year [4] - Enbrel total sales were $580 million, below the estimate of $645.48 million, reflecting a 29.7% decline year-over-year [4] - LUMAKRAS/LUMYKRAS total sales were $96 million, slightly below the estimate of $100.05 million, down 2% year-over-year [4] - TEZSPIRE total sales were $377 million, exceeding the estimate of $364.18 million, with a significant year-over-year increase of 40.2% [4] Stock Performance - Amgen's shares returned +0.7% over the past month, compared to the Zacks S&P 500 composite's +2.1% change, indicating a performance in line with the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]

Group 1 - Asian AI-linked companies' shares declined, influenced by falling U.S. peers and investor concerns over high valuations in crowded trades [1] - SoftBank's shares dropped by 10%, while Advantest's shares fell over 8% [1] - Palantir's shares decreased by approximately 8% despite exceeding third-quarter expectations, reflecting negative sentiment towards high valuations in the AI sector [2]

Financial Performance - Total revenues for Q3 2025 reached $9,557 million, a 12.4% increase from $8,503 million in Q3 2024[17] - Product sales increased to $9,137 million in Q3 2025, up 12.1% from $8,151 million in Q3 2024[17] - Net income for Q3 2025 was $3,216 million, representing a 13.6% increase compared to $2,830 million in Q3 2024[18] - Earnings per share (EPS) for Q3 2025 were $5.98 (basic) and $5.93 (diluted), compared to $5.27 and $5.22 in Q3 2024, reflecting increases of 13.5% and 13.6% respectively[17] - Comprehensive income for Q3 2025 was $3,338 million, compared to $2,649 million in Q3 2024, marking an increase of 26.0%[18] - Net income for the nine months ended September 30, 2025, was $6,378 million, a significant increase from $3,463 million in the same period of 2024, representing an 84.5% growth[43] - Total revenues for the nine months ended September 30, 2025, reached $26,885 million, up from $24,338 million in 2024, reflecting a 10.5% increase[43] Research and Development - Research and development expenses rose to $1,900 million in Q3 2025, a 31.0% increase from $1,450 million in Q3 2024[17] - Research and development expenses for the nine months ended September 30, 2025, totaled $5,130 million, an increase from $4,240 million in 2024, representing a 21.0% rise[43] - The company expects to continue to grow its spending on Later-Stage Clinical Programs as it advances its pipeline[197] Cash and Assets - Total assets as of September 30, 2025, were $90,141 million, a slight decrease from $91,839 million at the end of 2024[21] - Cash and cash equivalents decreased to $9,445 million from $11,973 million at the end of 2024[21] - Cash and cash equivalents at the end of the period were $9,445 million, up from $9,011 million at the end of the same period in 2024[27] Debt and Liabilities - Long-term debt decreased to $52,434 million from $56,549 million at the end of 2024, indicating a reduction in leverage[21] - Total principal amount of debt as of September 30, 2025, is $56.039 billion, down from $61.778 billion as of December 31, 2024[81] - Total carrying value of debt is $54.587 billion as of September 30, 2025, compared to $60.099 billion as of December 31, 2024[81] - Debt repayments for the three months ended September 30, 2025, totaled $1.5 billion, a decrease from $2.2 billion in the same period of 2024[83] - During the nine months ended September 30, 2025, debt repayments amounted to $5.0 billion, up from $3.6 billion in the same period of 2024[83] Dividends - The company declared dividends of $2.38 per share in Q3 2025, totaling $1,308 million[23] - Dividends paid during the nine months ended September 30, 2025, were $3,841 million, compared to $3,627 million in 2024, reflecting a 5.9% increase[27] - Quarterly cash dividends of $2.38 per share were declared in August 2025, March 2025, and December 2024, with the next payment scheduled for December 2025[88] Product Sales and Revenue Growth - Total product sales increased by 12% and 11% for the three and nine months ended September 30, 2025, respectively, driven by volume growth of 14% for both periods[153] - U.S. product sales reached $6,751 million for the three months ended September 30, 2025, up 13% from $5,979 million in 2024[152] - Prolia generated $1,139 million in revenue for the three months ended September 30, 2025, up from $1,045 million in 2024, reflecting a growth of 9.0%[45] - Repatha's revenue for the three months ended September 30, 2025, was $794 million, compared to $567 million in 2024, marking a significant increase of 40.1%[45] Legal and Regulatory Matters - The company has reached confidential settlement agreements regarding patent litigation with Samsung and Biocon, allowing them to launch their biosimilar products in the U.S.[122][126] - The company is involved in various legal proceedings and government investigations, which may have material adverse effects on its consolidated results of operations, financial position, or cash flows[118] - The FDA broadened the approved use of Repatha to include adults at increased risk for major adverse cardiovascular events due to uncontrolled low-density lipoprotein cholesterol[148] Economic and Market Conditions - Uncertain macroeconomic conditions, including inflation and rising healthcare costs, continue to pose challenges to Amgen's business[144] - The IRA and 340B Program are expected to negatively affect Amgen's business, with ENBREL and Otezla selected for Medicare price setting beginning in 2026 and 2027, respectively[145]